| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director | Director, 10% Owner
10 companies
Pfizer Inc last filed a Form 4 in March 2023, as 10% Owner at ALLO. The filings on record cover 10 companies.
At the last filing, the largest reported position was 1,427,639 shares of RYTM. Net of sales, the RYTM filings show accumulation of 40,000 shares.
Pfizer Inc has 12 Form 4 filings on record from August 2015 to March 2023, across 10 companies: 10% Owner at Pyxis Oncology (PYXS), 2023; 10% Owner at BioAtla (BCAB), 2020; 10% Owner at Viatris (VTRS), 2020, and 7 more.
The 40 reported transactions were 20 open-market sales, 11 conversions, 6 open-market purchases and 3 other transactions.
Counted by filing, the open-market trades come to 6 purchases worth about $17.5M and 4 sales worth about $743.9M.
The largest open-market purchase was 312,500 shares of ELVN at an average $16.00 on March 16, 2020, about $5.0M.
The largest open-market sale was 2,500,000 shares of ICUI at an average $209.25 on November 15, 2018, about $523.1M.
Shares as reported in the last Form 4 for each company; the most recent is from March 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 17, 2023 | PYXS Pyxis Oncology, Inc. | 10% Owner | Buy | 1,811,594 | $2.76 | $4,999,999.44 | +43.8% | |
| Jun 3, 2020 | QNCX Quince Therapeutics, Inc. | 10% Owner | Sell | 370,000 | $40.18 | $14,866,600.00 | -11.4% | |
| Mar 16, 2020 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Buy | 312,500 | $16.00 | $5,000,000.00 | +26.7% | |
| May 13, 2019 | QNCX Quince Therapeutics, Inc. | 10% Owner | Buy | 50,000 | $17.00 | $850,000.00 | +1.6% | |
| Nov 15, 2018 | ICUI Icu Medical Inc/de | Director | Sell | 2,500,000 | $209.25 | $523,125,000.00 | -100% | |
| Oct 15, 2018 | ALLO Allogene Therapeutics, Inc. | 10% Owner | Buy | 55,556 | $18.00 | $1,000,008.00 | +0.3% | |
| Aug 13, 2018 | ICUI Icu Medical Inc/de | Director, 10% Owner | Sell | 700,000 | $284.35 | $199,045,000.00 | -21.9% | |
| Oct 10, 2017 | RYTM Rhythm Pharmaceuticals, Inc. | 10% Owner | Buy | 40,000 | $17.00 | $680,000.00 | +2.9% | |
| Oct 6, 2015 | SYBX Synlogic, Inc. | 10% Owner | Buy | 714,285 | $7.00 | $4,999,995.00 | +46.4% | |
| Aug 10, 2015 | NGNE Neurogene Inc. | 10% Owner | Sell | 259,927 | $26.47 | $6,880,295.42 | -21.0% |